gefitinib has been researched along with leptomycin b in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (leptomycin b) | Trials (leptomycin b) | Recent Studies (post-2010) (leptomycin b) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 570 | 1 | 130 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, W; Liu, Z | 1 |
1 other study(ies) available for gefitinib and leptomycin b
| Article | Year |
|---|---|
Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Cycle Checkpoints; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Fatty Acids, Unsaturated; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Survivin; Time Factors | 2017 |